• Explore /
  • Poster
  • / A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914).

A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914).

Abstract Video & Slides Poster

Authors

null

Axel Bex

The Netherlands Cancer Institute, Amsterdam, Netherlands

Axel Bex , Paul Russo , Yoshihiko Tomita , Viktor Grünwald , Luz-Margarita Ramirez , Brent M. McHenry , Robert J. Motzer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT03138512

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS5099)

DOI

10.1200/JCO.2020.38.15_suppl.TPS5099

Abstract #

TPS5099

Poster Bd #

168

Abstract Disclosures

Similar Posters

First Author: Max Jameson-Lee

First Author: Tian Zhang

First Author: Nizar M. Tannir

First Author: Bruno Sangro